BUZZ-Xenon Pharma plunges after pausing trial enrollment due to side effects
XENE•Xenon Pharma shares tumble after trial enrollment pause
- Shares of Xenon Pharmaceuticals XENE.O slid 21.59% to $44.97 in extended trading.
- Xenon said it pauses enrollment of new patients in its depression and bipolar disorder studies after noticing neuropsychiatric side effects.
- Patients already enrolled in the studies continue treatment while the company reviews possible dose changes.
- The company said the pause is temporary and does not affect its epilepsy studies.
- As of the last close, the stock was up about 28% year to date.
Related News
BlackRock Taxable Municipal Bond Trust director Francis C. Mahoney files initial beneficial ownership statement
BBN•
Condor enters interline partnership with American Airlines for North America connections
AAL•
